Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study
- Equal contributors
1 Department of Internal Medicine, China Medical University Hospital, 40402 Taichung, Taiwan
2 Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan
3 Department of Pharmacy, College of Pharmacy, China Medical University, 40402 Taichung, Taiwan
4 School of Chinese Medicine, China Medical University, No. 91, Hsueh-Shih Road, 40402 Taichung, Taiwan
5 Graduate Institute of Integrated Medicine, China Medical University, 40402 Taichung, Taiwan
6 Department of Gynecology, China Medical University Hospital, 40447 Taichung, Taiwan
7 Department of Biotechnology, Asia University, 41354 Taichung, Taiwan
BMC Gastroenterology 2014, 14:113 doi:10.1186/1471-230X-14-113Published: 26 June 2014
The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNα-RBV).
We analyzed the association of the patients’ sustained viral responses (SVRs) to PEG-IFNα-RBV therapy with 2 single nucleotide polymorphisms (SNPs) in MRC-1 and 3 SNPs in IL-28B. We selected patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) with or without SVR.
Among the MRC-1 SNPs, rs691005 was found to be associated with SVR in HCV-1-infected patients (P < 0.0001). The IL-28B rs8099917 SNP was found to be associated with SVR in HCV-1- and HCV-2-infected patients (HCV-1, P < 0.0001; HCV-2, P = 0.002), while IL-28B rs955155 and rs10853728 SNPs were found to be associated with SVR in HCV-1-infected patients (P = 0.003) and HCV-2-infected patients (P = 0.02), respectively. We also identified an interaction between MRC-1 rs691005 and IL-28B rs8099917 (P = 0.001). The C-T haplotype was shown to have a positive effect on SVR in HCV-1-infected patients (OR = 1.77, 95% CI = 1.2, 2.62), whereas the T-G haplotype was shown to have a negative effect on SVR in HCV-1-infected patients (OR = 0.28, 95% CI = 0.14, 0.58).
These results suggest that SNPs of IL-28B and MRC-1 can be used as genetic markers for predicting the outcome of PEG-IFNα-RBV treatment of HCV infections.